US64132R4048 - Common Stock
NEUROBO PHARMACEUTICALS INC
NASDAQ:NRBO (4/19/2024, 7:06:56 PM)
After market: 3.65 +0.28 (+8.31%)3.37
-0.07 (-2.03%)
NeuroBo Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-08-05. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The firm is focused primarily on therapies for cardiometabolic diseases. Its therapeutics programs include DA-1241 and DA-1726. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist. OXM is a naturally occurring, 37-amino acid peptide hormone that is released from the gut after ingestion of a meal, activating both the GLP-1 and glucagon receptors, prompting reduced food intake as well as an increase in energy expenditure, potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists. Each of DA-1241 and DA-1726 is being developed for the treatment of nonalcoholic steatohepatitis.
NEUROBO PHARMACEUTICALS INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS 02116
P: 18577029600
CEO: Richard Kang
Employees: 4
Website: https://www.neurobopharma.com/
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose...
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of...
NeuroBo Pharmaceuticals (NRBO) receives site approval for a Phase 1 study of obesity drug candidate DA-1726, causing shares to surge 14% in premarket trading. Read more here.
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
Here you can normally see the latest stock twits on NRBO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: